Shuttle Pharmaceuticals Accelerates Equity Payment in Asset Deal

An announcement from Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) is now available.

On December 23, 2025, Shuttle Pharmaceuticals Holdings, Inc. amended an existing asset purchase agreement involving its Canadian subsidiary 1563868 B.C. Ltd., Canadian seller 1542770 BC Ltd., and a seller guarantor, accelerating part of the first installment payment by issuing 320,496 shares of common stock. The transaction, which closed the same day, resulted in the seller receiving shares equal to 19.99% of Shuttle’s outstanding common stock at a deemed value of $1.76 per share, with the remaining portion of the first installment to be paid in cash under the original terms, signaling a material equity-based consideration structure executed under securities law exemptions for unregistered offerings.

Spark’s Take on SHPH Stock

According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.

Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.

To see Spark’s full report on SHPH stock, click here.

More about Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical and life sciences industry, focusing on the development and commercialization of oncology-related therapeutics and technologies, with activities that include structuring cross-border transactions through wholly owned subsidiaries in Canada.

Average Trading Volume: 334,510

Technical Sentiment Signal: Sell

Current Market Cap: $3M

For an in-depth examination of SHPH stock, go to TipRanks’ Overview page.